36 related articles for article (PubMed ID: 25385241)
21. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
22. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2010 Jul; 11():111. PubMed ID: 20630055
[TBL] [Abstract][Full Text] [Related]
25. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.
Elens L; van Gelder T; Hesselink DA; Haufroid V; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(1):47-62. PubMed ID: 23252948
[TBL] [Abstract][Full Text] [Related]
26. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.
Novillo A; Romero-Lorca A; Gaibar M; Bahri R; Harich N; Sánchez-Cuenca D; Esteban E; Fernández-Santander A
Int J Biol Markers; 2015 Feb; 30(1):e148-51. PubMed ID: 25385241
[TBL] [Abstract][Full Text] [Related]
27. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
28. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
Lee SJ; Goldstein JA
Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
[TBL] [Abstract][Full Text] [Related]
29. Statin regulation of CYP3A4 and CYP3A5 expression.
Willrich MA; Hirata MH; Hirata RD
Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
[TBL] [Abstract][Full Text] [Related]
30. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
Maslub MG; Radwan MA; Daud NAA; Sha'aban A
Eur J Med Res; 2023 Sep; 28(1):381. PubMed ID: 37759317
[TBL] [Abstract][Full Text] [Related]
31. CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis.
Zhou LP; Yao F; Luan H; Wang YL; Dong XH; Zhou WW; Wang QH
Tumour Biol; 2013 Apr; 34(2):649-60. PubMed ID: 23179402
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
